By Helena Smolak
Merck will partner with Chinese biotech Abbisko Therapeutics to market and sell the bone-tumor treatment pimicotinib globally, expanding its commercialization rights for the drug beyond Asia.
The German pharmaceutical company said Friday that it would pay Abbisko an option fee of $85 million.
The companies will explore additional indications for pimicotinib, such as chronic graft-versus-host disease--a systemic disorder where transplanted immune cells recognize the recipient's body as foreign--after a recent late-stage study showed that the treatment significantly improved the response rate compared with placebo among patients with tenosynovial giant cell tumor, a benign tumor that grows around the joints.
Merck entered into an agreement with Abbisko Therapeutics in 2023 for the commercialization rights in Mainland China, Hong Kong, Macau, and Taiwan. Pimicotinib has been granted breakthrough therapy designation by China's National Medical Products Administration and the U.S. Food and Drug Administration.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
March 28, 2025 02:32 ET (06:32 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。